Secukinumab Placebo

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Axial SpondyloarthritisEnthesitisPsoriatic Arthritis

Phase 3

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site

CompletedNCT02771210

Novartis PharmaceuticalsAxial Spondyloarthritis, Enthesitis, Psoriatic Arthritis

Start: 2016-08-30End: 2019-12-11Updated: 2021-05-03

Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.

CompletedNCT04711902

Novartis PharmaceuticalsPsoriatic Arthritis

Start: 2021-06-24End: 2023-03-10Updated: 2024-10-09

Related Papers

Efficacy and safety of secukinumab in patients with active psoriatic arthritis at Week 16 and up to 52 weeks: Results from a Phase III, randomized, double-blind, placebo-controlled bridging study in China

Chinese Medical Journal2026-03-24

Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial.

2022-05-164 citations

Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial

Lara D. Veeken2021-10-2924 citations

Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial

BMC Musculoskeletal Disorders2020-11-2115 citations

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.

2019-12-0416 citations